Intervet/Schering-Plough Animal Health has announced that it has received approval for the intramuscular (IM) route of administration of Nuflor Minidose 450 mg/ml, a florfenicol-containing broad-spectrum antibiotic for the management of bovine respiratory disease (BRD).

Nuflor Minidose was approved initially in 2008 for subcutaneous (SC) use only and the now approved IM administration route is a line extension. According to Intervet/Schering Plough, IM administration (20 mg/kg administered twice, 48h apart) offers additional flexibility for the veterinary surgeon when treating cattle for BRD.

The company adds that Nuflor Minidose is the florfenicol injectable formulation which offers the lowest injection volume, which in particular is practical when treating heavier animals (thereby avoiding large injection volumes). The withdrawal period after IM administration of NUFLOR Minidose is only 37 days and is considerably shorter as compared to 64 days after SC use (40 mg/kg body weight injected once).

Francis Adriaens, Global Marketing Director, Global Ruminants Business Unit at Intervet/Schering-Plough Animal Health said: "Our customers requested the IM claim when Nuflor Minidose was first introduced and we are delighted to be able to recommend this route of administration hence forth."

Nuflor Minidose is indicated for preventive and therapeutic treatment of BRD in cattle caused by Mannheimia haemolytica, Pasteurella multicoda and Histophilus somni susceptible to florfenicol. The presence of the disease in the herd should be confirmed before administering preventive treatment.

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.